Shares of WAVE Life Sciences (NASDAQ:WVE) were unchanged at $7.97 after the company reported Q1 results.
Earnings per share decreased 1.47% over the past year to ($1.38), which missed the estimate of ($1.20).
Revenue of $4,161,000 rose by 37.51% from the same period last year, which missed the estimate of $6,050,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 11, 2020
Time: 07:03 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/evfwy3gr
Company's 52-week high was at $39.98
52-week low: $6.61
Price action over last quarter: down 2.45%
WAVE Life Sciences Ltd is a preclinical biopharmaceutical company based in Singapore. It owns a diverse pipeline of nucleic acid therapeutics meant to address rare genetic diseases related to the central nervous system, muscles, eyes, liver, and skin. Its nucleic acid therapeutics target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.